SNDX - シンダックス・ファ―マシュ―ティカルズ （Syndax Pharmaceuticals Inc.）SNDXのニュース
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2023/03/06 21:05:00 PR Newswire
WALTHAM, Mass., March 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2023 the Company granted an inducement award to purchase up to…
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call Transcript 2023/03/03 20:44:05 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ETCompany ParticipantsSharon Klahre - Head, Investor RelationsMichael Metzger -…
Syndax Pharmaceuticals: 2023 Is A Pivotal Year 2023/03/01 18:14:51 Seeking Alpha
Syndax has 2 pivotal trials with data readouts in 2023, with possible regulatory filings. Check out why I might be a buyer of SNDX stock at these prices.
Syndax: Q4 Earnings Snapshot 2023/02/28 23:20:20 WTOP
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $39.2 million…
Syndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04 2023/02/28 21:50:37 Seeking Alpha
Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of -$0.62 beats by $0.04.As of December 31, 2022, Syndax had cash, cash equivalents, short-term and long-term investments…
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 2022/06/30 17:47:00 Investor''s Business Daily
Syndax Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Keith Goldan joins Syndax Pharmaceuticals as CFO 2022/06/13 11:37:34 Seeking Alpha
Syndax Pharmaceuticals (SNDX) has appointed Keith Goldan as CFO, effective immediately.Goldan holds nearly 30 years of leadership and operational experience at several…
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer 2022/06/13 11:30:00 PR Newswire
WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of…
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call Transcript 2022/05/10 00:13:09 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael…
Syndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2022/05/09 22:56:26 Seeking Alpha
The following slide deck was published by Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call Transcript 2022/05/10 00:13:09 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael…
Syndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2022/05/09 22:56:26 Seeking Alpha
The following slide deck was published by Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals GAAP EPS of -$0.63 2022/05/09 20:15:23 Seeking Alpha
Syndax Pharmaceuticals press release (SNDX): Q1 GAAP EPS of -$0.63.Total operating expenses of $36.85M.
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update 2022/05/09 20:05:00 PR Newswire
– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed…